T-13 and T-26, the novel taxanes with improved oral bioavailability in rats

Abstract

www.nature.com/scientificreports www.nature.com/scientificreports/ half-life of the terminal phase (t 1/2 ) and the mean residence time (MRT). Other parameters such as maximum plasma concentration (C max ) and the time to reach C max (T max ) were also analyzed after oral administration in rats. Statistical analysis.The data were presented as mean ± standard deviation of at least three experiments.The Mann-Whitney U-test was used to investigate statistical differences at a significance level of P < 0.05. All data processing was performed using the statistical package for social sciences (SPSS) software. ResultsThe mean plasma concentration-time profiles and the pharmacokinetic parameters of T-13 and T-26 after intravenous (5 mg/kg) and oral administration (60 mg/kg) in rats were presented in Fig. 2 and Table 1, respectively. As reflected in Table 1, T-13 and T-26 displayed similar values and demonstrated a higher capacity to promote the absorption in vivo. Finally, the oral bioavailability of T-13 and T-26 were calculated to be 10.71% and 65.79%, respectively, which were both higher than 5% for paclitaxel 15 . Scientific RepoRtS |(2020) 10:3211 | https://doi.

Molecular imaging in Alzheimer's disease

“…Regarding diagnostic accuracy, datasets two and three indicated effectiveness of the rSDBOLD in the dataset one's regions of interest in differentiating Alzheimer Disease patients and controls. It is shown that the rSDBOLD is quite precise [2]. fMRI was able to clearly differentiate Alzheimer's disease patients from the controls, showing its potential as a biomarker for the disease.…”

Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

“…These include DHP107, a mixture of paclitaxel with monoolein/tricarprylin/Tween ® 80 (DAE HWA Pharmaceutical Co., Ltd., Seoul, Republic of Korea), ModraDoc001, an amalgamation of docetaxel with polyvinylpyrrolidone-K30 and sodium lauryl sulphate [ 127 ], Orataxel (IDN-5109, BAY 59-8862) [ 128 ], Milataxel (MAC-321) [ 129 ], BMS-275183 [ 130 ], and tesetaxel (DJ-927, Genta, LaJolla, CA, USA) [ 131 ], among others. Compounds T13 and T26 have improved oral bioavailability in rats [ 132 ]. Unfortunately, the oral bioavailability of these agents in human clinical trials appears to vary significantly.…”